- Home
- ZVSA vs ATNF Comparison
ZVSA vs ATNF Comparison
Compare ZVSA & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- ATNF
- Stock Information
- Founded
- ZVSA 2014
- ATNF 2016
- Country
- ZVSA United States
- ATNF United States
- Employees
- ZVSA N/A
- ATNF N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- ATNF Health Care
- Exchange
- ZVSA Nasdaq
- ATNF Nasdaq
- Market Cap
- ZVSA 2.5M
- ATNF 2.6M
- IPO Year
- ZVSA N/A
- ATNF N/A
- Fundamental
- Price
- ZVSA $1.10
- ATNF $1.74
- Analyst Decision
- ZVSA Strong Buy
- ATNF
- Analyst Count
- ZVSA 1
- ATNF 0
- Target Price
- ZVSA $240.00
- ATNF N/A
- AVG Volume (30 Days)
- ZVSA 243.8K
- ATNF 128.8K
- Earning Date
- ZVSA 11-14-2024
- ATNF 02-13-2025
- Dividend Yield
- ZVSA N/A
- ATNF N/A
- EPS Growth
- ZVSA N/A
- ATNF N/A
- EPS
- ZVSA N/A
- ATNF N/A
- Revenue
- ZVSA N/A
- ATNF N/A
- Revenue This Year
- ZVSA N/A
- ATNF N/A
- Revenue Next Year
- ZVSA N/A
- ATNF $54.15
- P/E Ratio
- ZVSA N/A
- ATNF N/A
- Revenue Growth
- ZVSA N/A
- ATNF N/A
- 52 Week Low
- ZVSA $0.98
- ATNF $1.16
- 52 Week High
- ZVSA $25.00
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- ZVSA 41.83
- ATNF 32.45
- Support Level
- ZVSA $0.99
- ATNF $1.69
- Resistance Level
- ZVSA $1.20
- ATNF $2.26
- Average True Range (ATR)
- ZVSA 0.08
- ATNF 0.19
- MACD
- ZVSA 0.04
- ATNF -0.02
- Stochastic Oscillator
- ZVSA 54.55
- ATNF 4.61
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.